|
|
NEWS
July 12, 2010
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.
Urine is an attractive source for clinical proteomics/peptidomics. Due to the lack of comparable data sets from large cohorts, the development of clinical proteomics was yet greatly hindered. In this publication the establishment of a reproducible, high-resolution method for peptidome analysis of naturally occurring human urinary peptides and proteins using samples from 3,600 individuals analyzed by capillary electrophoresis coupled to mass spectrometry (CE-MS) is reported. All processed data being stored in a database (currently 5,010 urinary peptides) serve as a pool of potential classifiers for diagnosis and monitoring of various diseases. Using this information, the authors were able to define urinary peptide biomarkers for chronic kidney diseases (CKD) allowing diagnosis of these diseases with high accuracy (85.5% sensitivity and 100% specificity). These results indicate the potential usefulness of CE-MS for clinical applications in the analysis of naturally occurring urinary peptides.
Full Text PDF 
May 6, 2009
MOSAIQUES and U.S. FDA describe detection of drug-induced side effects in early phase animal models
MOSAIQUES’ CE/MS technology paves the way for early assessment of drug-induced side effects and helps ensuring patient’s safety from the very beginning of preclinical research.
View Press Release
May 5, 2009
Profiling of rat urinary proteomic patterns associated with drug-induced nephrotoxicity using capillary electrophoresis coupled with mass spectrometry as a potential model for detection of drug-induced adverse effects
Our study strongly suggests that (drug-induced) nephrotoxicity can be detected with high accuracy in laboratory rodents using urinary proteome analysis. The effects observed are very similar to those seen in corresponding human diseases and similar approaches may be very helpful in evaluating drug-induced organ damage in preclinical animal models ...
View Publisher Website 
April 29, 2009
American Heart Association: Urine screening test may one day predict coronary artery disease
Proteome analysis, a screening requiring only a patient’s urine specimen, shows promise as a reliable and noninvasive way to diagnose atherosclerosis and coronary artery disease in the future, according to research presented at the American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2009 ...
View Press Release
February 20, 2009
MOSAIQUES and U.S. Food and Drug Administration (FDA) sign contract for collaboration in discovery and validation of biomarkers for assessment of drug toxicity
mosaiques diagnostics and therapeutics AG, a global leading proteomics innovations company, announces the signing of a collaborative agreement with the U.S. Food and Drug Administration.
View Press Release
January 14, 2009
Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease
Abstract Background: In this study we sought to validate urinary biomarkers for diabetes and two common complications, coronary artery disease (CAD) and diabetic nephropathy (DN) …
View Abstract 
October 30, 2008
Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developments
Proteome analysis has emerged as a powerful technology to decipher biological processes. One of the main goals is to discover biomarkers for diseases from tissues and body fluids. However, the complexity and wide dynamic range of protein expression present an enormous challenge to separation technologies and mass spectrometry (MS) ...
View Abstract
October 7, 2008
Establishment of a European Network for Urine and Kidney Proteomics
Chronic kidney diseases (CKD) constitute a major and global healthcare threat, which is expected to be amplified in the near future owing to the rising numbers of aged individuals and the increased incidence of type II diabetes. It is also likely to have an impact on the overall mortality from chronic, non-communicable, disease worldwide ...
View Abstract
September 24, 2008
Fragments of Collagen allow discrimination of superficial and invasive bladder cancer tumors
Mosaiques diagnostics and an international network of renowned scientists revealed urinary fragments of collagen alpha-1(I) and alpha-1(III) to distinguish between superficial and invasive bladder cancer tumors.
View News
August 15, 2008
Biomarkers unmask Biological Age
Newly identified peptides represent powerful biomarkers of human aging associated with telomere shortening and could be used in the clinic to improve personalized therapies in the elderly. Furthermore, the new test enables the assessment of food supplements, pharmacological therapies, and rules of behavior to retard premature aging.
View Press Release (German)
August 12, 2008
Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease
Telomere dysfunction limits the proliferative capacity of human cells by activation of DNA damage responses, inducing senescence or apoptosis. In humans, telomere shortening occurs in the vast majority of tissues during aging, and telomere shortening is accelerated in chronic diseases that increase the rate of cell turnover ...
View Abstract
July 14, 2008
“Human Urine Proteome Database” goes online
mosaiques AG enables deep insights into human proteome / “Escape from looming crisis of the health care systems.”
View Press Release (German)
July 10, 2008
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics
Owing to its availability, ease of collection, and correlation with pathophysiology of diseases, urine is an attractive source for clinical proteomics. However, many proteomic studies have had only limited clinical impact, due to factors such as modest numbers of subjects, absence of disease controls, small numbers of defined biomarkers, and diversity of analytical platforms ...
View Abstract
July 10, 2008
The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy
Diabetes represents one of the main chronic diseases worldwide. Diabetes and its associated complications may be detectable even at early stages in the urinary proteome. In this article we review the current literature on urinary proteomics applied to the study of diabetes and diabetic complications ...
View Abstract
July 1, 2008
Urinary proteomics in diabetes and CKD
Urinary biomarkers for diabetes, diabetic nephropathy, and nondiabetic proteinuric renal diseases were sought. For 305 individuals, biomarkers were defined and validated in blinded data sets using high-resolution capillary electrophoresis coupled with electrospray-ionization mass spectrometry ...
View Abstract
May 31, 2008
Exploring the uremic toxins using proteomic technologies
Kidney failure leads to the uremic syndrome that is the clinical expression of the malfunction of vital organs due to the accumulation of uremic toxins, which are normally cleared by the kidneys. Progressively more uremic retention solutes have been identified and their potential toxicity has been characterized ...
View Abstract
May 31, 2008
Identification of urinary biomarkers by proteomics in newborns: use in obstructive nephropathy
An important issue in congenital unilateral ureteropelvic junction (UPJ) obstruction, a frequent pathology in newborns, is whether infants should undergo surgery. Non-invasive biomarkers to reduce or replace the current invasive clinical exploration are not available ...
View Abstract
May 31, 2008
Capillary electrophoresis coupled to mass spectrometry for biomarker discovery and diagnosis of kidney diseases
The main focus of urinary proteome analysis in nephrology is currently on detection and identification of polypeptides that significantly alter (in abundance, distribution, etc.) during (patho)physiological changes of the kidney structure and/or function. Capillary electrophoresis coupled online to electrospray ionization time-of-flight mass spectrometry (CE-MS) was applied to human urine to identify biomarkers for clinical diagnostics ...
View Abstract
May 1, 2008
A bench to bedside view of uremic toxins
Reviewing the current picture of uremic toxicity reveals its complexity. Focusing on cardiovascular damage as a model of uremic effects resulting in substantial morbidity and mortality, most molecules with potential to affect the function of a variety of cell types within the vascular system are difficult to remove by dialysis ...
View Abstract
April 1, 2008
Capillary electrophoresis mass spectrometry as a potential tool to detect lithium-induced nephropathy: Preliminary results
Lithium remains the treatment of choice for many patients suffering from bipolar disorder. However, long-term treatment with lithium carries the potential to cause renal and thyroid dysfunction …
View Abstract
March 7, 2008
Innovative urine analysis improves prostate cancer diagnosis
Mosaiques´ CE/MS technology demonstrates its groundbreaking capabilities in a blinded prospective multicenter study with more than 500 patients in order to improve prostate cancer diagnosis.
View Abstract
February 28, 2008
Advances in urinary proteome analysis and biomarker discovery
Noninvasive diagnosis of kidney diseases and assessment of the prognosis are still challenges in clinical nephrology. Definition of biomarkers on the basis of proteome analysis, especially of the urine, has advanced recently and may provide new tools to solve those challenges ...
View Abstract
February 1, 2008
Human Proteinpedia enables sharing of human protein data
Proteomic technologies, such as yeast twohybrid, mass spectrometry (MS), protein/peptide arrays and fluorescence microscopy, yield multi-dimensional data sets, which are often quite large and either not published or published as supplementary information that is not easily searchable. Without a system in place for standardizing and sharing data, it is not fruitful for the biomedical community to contribute these types of data to centralized repositories ...
View Abstract
January 4, 2008
Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform
Bladder cancer (BCa) is one of the most prevalent malignancies worldwide, mostly due to its high recurrence rates. In consequence, the necessity of repeated screening for reappearance demonstrates the urgent need for novel biomarkers as alternatives to invasive standard procedures ...
View Abstract
December 4, 2007
REPORT - Grand Rounds in Proteomics at the FDA
Renowned experts from industry and academia discussed the recent news and concepts in the field of clinical proteomics to train FDA reviewers on current applications for the future review of proteomic data.
View Abstract
December 1, 2007
Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases
We evaluated the utility of SDS-PAGE/Western blot and CE coupled with MS (CE-MS) for detection of urinary polypeptide biomarkers of renal disease in patients with IgA-associated glomerulonephritides. In a reference cohort of 402 patients with various renal disorders and 207 healthy controls, we defined CE-MS patterns of renal damage and IgA nephropathy (IgAN) ...
View Abstract
November 9, 2007
Urine analysis enables cardiovascular risk assessment
Mosaiques diagnostics and an international network of renowned scientists from the British Heart Foundation (UK) and Baker Heart Research Institute (Australia) developed an innovative approach to distinguish between presence and absence of coronary artery disease by the straightforward analysis of urine.
View Press Release
October 31, 2007
Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future
Sparked by the article from Lescuyer and colleagues in a recent issue, we aim here to further encourage interest in and discussion of clinically relevant biomarker research. We express our view on proteomics for biomarker discovery by addressing multiple relevant issues, including the inherent differences between biological fluids (and how these differences affect current analytical approaches) and experimental design to maximize the efficiency of moving from the bench to the bedside ...
View Abstract
August 17, 2007
Mass spectrometry based proteomics in urine biomarker discovery
All organisms contain 1,000s of proteins and peptides in their body fluids, which undergo disease-specific changes. Advances in the understanding of the functional relevance of these polypeptides under different (patho)physiological conditions and the identification of indicative changes with disease would greatly enhance diagnosis and therapy ...
View Abstract
August 10, 2007
Biomarkers for prostate cancer
Novel biomarkers for prostate cancer (PCa) are currently being assessed for utility in PCa diagnosis. This article aims to provide concise information on the current findings that impact prostate cancer research …
View Abstract
July 20, 2007
Clinical Proteomics in Diabetes and Its Complications (National Institute of Health, Bethesda, MD, USA)
Prof. Dr. Dr. Harald Mischak: Scientific oral Presentation "Urinary Proteome Analysis Using Capillary Electrophoresis Coupled Mass Spectrometry for the Detection of Diabetes-Associated Pathologies"
View Presentation
July 10, 2007
Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases
IgA nephropathy is the most common primary glomerulonephritis and is a frequent cause for chronic kidney disease in children and young adults. Glomerular deposition of IgA also characterizes other renal disorders, including Henoch-Schoenlein purpura nephritis and immune-complex glomerulonephritis afflicting patients with liver disease due to chronic infection with the hepatitis C virus ...
View Abstract
July 10, 2007
High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine
All organisms contain thousands of proteins and peptides in their body fluids. A deeper insight into the functional relevance of these polypeptides under different physiological and pathophysiological conditions and the discovery of specific peptide biomarkers would greatly enhance diagnosis and therapy of specific diseases ...
View Abstract
June 8, 2007
Mosaiques diagnostics and Bayer HealthCare publish a novel proteomics-based approach for the evaluation of rat urine
An innovative procedure for analyzing rat urine provides novel insights into body fluids of animal models and enables the assessment of toxicological and physiological effects of pharmaceutical compounds in preclinical development.
View Abstract
June 5, 2007
Review on uraemic solutes II--variability in reported concentrations: causes and consequences
The aim of this manuscript is to initiate a constructive discussion about deviations in measured concentrations of uraemic solutes; these deviations, if not perceived or handled appropriately, may lead to incorrect interpretations of the pathophysiological role of uraemic solutes and/or to erroneous therapeutic decisions ...
View Abstract
May 1, 2007
CE - a multifunctional application for clinical diagnosis
CE has been used widely as an analytical tool with high separation power taking advantage of size, charge-to-size ratio, or isoelectric point of various analytes …
View Abstract
April 16, 2007
Mosaiques diagnostics GmbH and MHH investigators win cooperation award of the federal state of Lower Saxony
Urin test enables the early diagnosis of a life-threatening complication after stem cell transplantation.
View Press Release (German)
April 13, 2007
Grand Rounds in Proteomics at the FDA
A pilot process for biomarker qualification at the FDA should elucidate the potential of proteomic data for the drug development and evaluation process.
View Press Release
March 26, 2007
Improved safety for leukaemia patients after allogeneic hematopoietic stem cell transplantation
A perilous threat for hematopoietic stem cell recipients is the acute Graft-versus-Host Disease – The Hannover Medical School developed together with the mosaiques diagnostics & therapeutics AG an early diagnosis of this momentous disease.
View Press Release
March 12, 2007
Tracing kidney diseases
Fast and accurate detection of kidney diseases – The DiaPat® technology revolutionises the examination of the renal system.
View Press Release
March 5, 2007
Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Acute graft-versus-host disease (aGvHD) contributes significantly to morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Diagnosis of GvHD is mainly based on clinical features and tissue biopsies. A noninvasive, unbiased laboratory test for GvHD diagnosis does not exist ...
View Abstract
February 27, 2007
Worldwide standards for clinical proteome analyses
The dream of individual medicine gets the scientific basis.
View Press Release
January 22, 2007
Clinical proteomics: A need to define the field and to begin to set adequate standards
The aim of this manuscript is to initiate a constructive discussion about the definition of clinical proteomics, study requirements, pitfalls and (potential) use. Furthermore, we hope to stimulate proposals for the optimal use of future opportunities and seek unification of the approaches in clinical proteomic studies. We have outlined our collective views about the basic principles that should be considered in clinical proteomic studies, including sample selection, choice of technology and appropriate quality control, and the need for collaborative interdisciplinary efforts involving clinicians and scientists ...
View Abstract